Race To Build Zinbryta's MS Market Share Ahead Of Even More Competition
Executive Summary
New multiple sclerosis drug Zinbryta adds a European approval to its regulatory status, but is targeting a market where there are already various options for treating relapsing-remitting MS patients.
You may also be interested in...
Biogen, AbbVie Withdraw Struggling MS Drug Zinbryta Due To Safety Issues
Antibody was approved in the US with a liver safety warning while EU regulators recently limited the drug's use. Now, EMA has begun an urgent review of reports of inflammatory brain disorders related to Zinbryta.
Biogen/AbbVie MS Drug Zinbryta Approved; Faces Crowded Market, Liver Concerns
Biogen Inc. and AbbVie Inc. may have won the FDA's approval to market Zinbryta (daclizumab) as a treatment for multiple sclerosis, but the firms are facing significant barriers in marketing the drug, which is entering an already crowded field and coming to the marketplace with a black-box warning about serious adverse liver risks, limiting its sales potential.
Biogen's Zinbryta Gets EU Nod – But Where Will It Fit In?
Biogen and AbbVie Inc.'s multiple sclerosis therapy, Zinbryta (daclizumab), has been given a green light for use in Europe – but what gap can this new drug fill in a crowded therapy space?